Clinical Trials Browser

Phase 1/2 × Active not recruiting × Mesna × Clear all

NCT03573700 2025-11-18

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Phase 1/2 Active not recruiting

24 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma